Abbvie Inc. · NYSE:ABBV
Abbvie — Merger or Acquisition (June 2026)
15 slides from Abbvie's merger presentation, Jun 22, 2026
Slide 1: Acquisition of Apogee Therapeutics
1 Acquisition of Apogee Therapeutics June 22, 2026
Slide 2: Forward-looking statements
June 22, 2026 2 This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All state
Slide 3: Strong Strategic Fit for AbbVie
June 22, 2026 3 Strong Strategic Fit for AbbVie Leverages AbbVie’s regulatory and clinical expertise, commercial capabilities and international infrastructure to maximize Apogee’s high-value assets Complements AbbVie’s Immunology pipeline by adding multiple potentially differentiated assets to treat
Slide 4: Apogee Overview
June 22, 2026 4 Apogee Overview Clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing for the treatment of atopic dermatitis, asthma and other inflammatory conditions • Portfolio of long-acting antibodies targeting well-established biolo
Slide 5: Apogee Well-Aligned With AbbVie Strategic Goals in Immunology
June 22, 2026 5 Apogee Well-Aligned With AbbVie Strategic Goals in Immunology ELEVATE CARE OFFER CONVENIENCE DEVELOP CURES Rinvoq AA, Vitiligo, HS, SLE Lutikizumab HS Skyrizi SubQ Induction in IBD B-cell Depletion in Rheumatology Oral Peptides for PsO, PsA & IBD Novel Combinations in Dermatology IL2
Slide 6: Apogee Highly Complementary to AbbVie's Immunology Pipeline
June 22, 2026 6 Apogee Highly Complementary to AbbVie’s Immunology Pipeline Phase 1 Phase 2 Phase 3 Under Regulatory Review ABBVIE IMMUNOLOGY PROGRAMS ABBV-313 (IL13/IL31R) Ph1 start Q3 2026 AD ABBV-142 (LPAR1) IPF Lutikizumab (IL1) HS Rinvoq (JAKi) Alopecia Areata ABBV-319 (CD19 ADC) SLE, SjD ABBV-
Slide 7: Atopic Dermatitis
June 22, 2026 7 Atopic Dermatitis • ~$18 billion global revenues growing more than 15% annually • ~2.5x more moderate-to-severe patients than psoriasis • ~8% penetration for advanced therapies • Only ~20% of patients simultaneously achieve itch and skin improvement (NRS 0/1 & EASI90) on today’s best
Slide 8: Zumilokibart (APG777) Extended Half-life Anti-IL13 Antibody
June 22, 2026 8 Zumilokibart (APG777) Extended Half-life Anti-IL13 Antibody Being Developed as a Monotherapy or Combination Therapy in Dermatology, Respiratory and Other Immune-Mediated Diseases • Across a robust, reproducible two-part Ph2 study, zumilokibart demonstrated strong lesion and itch cont
Slide 9: Zumilokibart APEX Part B: Response Rates Versus Marketed AD Biologics
June 22, 2026 9 Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part B Numerically Higher Absolute Response Rates and Placebo-Adjusted Efficacy Across Key Endpoints Compared to Currently Marketed AD Biologics 23% 17% 14% 30% 43% 38% 34% 14% Zumi Ebglyss Dupixent Nemluvio EASI 75 Responders at 1
Slide 10: Zumilokibart APEX Part A: Improvement Through Week 52
June 22, 2026 10 Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part A Zumilokibart 360mg Q24W Zumilokibart 360mg Q12W Continuous Improvement Across All Endpoints Through Week 52 Zumilokibart 360mg Q24W Zumilokibart 360mg Q12W Zumilokibart 16-Week Induction Durable Maintenance of Responses wit
Slide 11: Asthma Represents a Large and Underserved Market Opportunity
June 22, 2026 11 Asthma Represents a Large and Underserved Market Opportunity to Grow Market with Commercial Investment and Innovation Significant Opportunity in Asthma Market Treatment Options for Type 2 Low Asthma Elevated Efficacy in Type 2 High Asthma Improved Adherence • Ongoing exacerbations,
Slide 12: APG273 Dual IL13 / TSLP Inhibition in Asthma
June 22, 2026 12 APG273 (Zumilokibart + APG333) Dual IL13 / TSLP Inhibition Could Provide Transformational Efficacy for Type 2 High and Low Asthma Patients with Significantly Improved Q12W Dosing • Dual blockage of two clinically validated asthma disease pathways (IL13 / TSLP) has potential for enha
Slide 13: Transaction and Financial Overview
June 22, 2026 13 Transaction and Financial Overview • AbbVie has agreed to acquire all outstanding shares of Apogee for a purchase price of $135.11 per share in an all-cash transaction • Premium of approximately 49% to the closing price on June 18, 2026 • Purchase price of $10.9B; Implied transactio
Slide 14: Key Takeaways
June 22, 2026 14 Key Takeaways A strong strategic fit for AbbVie that represents an attractive opportunity to acquire a pipeline of potentially differentiated assets focused on treating inflammatory conditions • Complements AbbVie’s Immunology pipeline by adding a portfolio of long-acting, high-effi
Slide 15: Slide 15